Capital Management Associates Inc Invests $249,000 in Axon Enterprise, Inc (NASDAQ:AXON)

Capital Management Associates Inc bought a new stake in Axon Enterprise, Inc (NASDAQ:AXON - Free Report) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 474 shares of the biotechnology company's stock, valued at approximately $249,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in AXON. Crossmark Global Holdings Inc. lifted its stake in shares of Axon Enterprise by 18.5% during the 1st quarter. Crossmark Global Holdings Inc. now owns 4,816 shares of the biotechnology company's stock valued at $2,533,000 after buying an additional 752 shares in the last quarter. Pacific Point Advisors LLC purchased a new stake in shares of Axon Enterprise during the 1st quarter valued at approximately $526,000. Financial Counselors Inc. lifted its stake in shares of Axon Enterprise by 38.9% during the 1st quarter. Financial Counselors Inc. now owns 521 shares of the biotechnology company's stock valued at $274,000 after buying an additional 146 shares in the last quarter. TD Private Client Wealth LLC lifted its stake in shares of Axon Enterprise by 7.8% during the 1st quarter. TD Private Client Wealth LLC now owns 1,123 shares of the biotechnology company's stock valued at $591,000 after buying an additional 81 shares in the last quarter. Finally, Olde Wealth Management LLC purchased a new stake in shares of Axon Enterprise during the 1st quarter valued at approximately $110,000. 79.08% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, CAO Jennifer H. Mak sold 75 shares of the firm's stock in a transaction dated Friday, June 13th. The shares were sold at an average price of $771.81, for a total value of $57,885.75. Following the completion of the sale, the chief accounting officer directly owned 15,240 shares of the company's stock, valued at approximately $11,762,384.40. This trade represents a 0.49% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, President Joshua Isner sold 905 shares of the firm's stock in a transaction dated Tuesday, June 17th. The stock was sold at an average price of $776.39, for a total transaction of $702,632.95. Following the completion of the sale, the president directly owned 268,735 shares of the company's stock, valued at approximately $208,643,166.65. This represents a 0.34% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 44,642 shares of company stock worth $30,500,428. 5.70% of the stock is currently owned by insiders.

Axon Enterprise Trading Up 0.8%

Shares of Axon Enterprise stock traded up $6.68 during trading on Monday, reaching $802.16. The company's stock had a trading volume of 452,802 shares, compared to its average volume of 707,057. Axon Enterprise, Inc has a 52-week low of $279.02 and a 52-week high of $830.21. The company has a market cap of $62.45 billion, a price-to-earnings ratio of 193.76, a PEG ratio of 91.57 and a beta of 1.29. The firm's 50-day moving average is $736.97 and its two-hundred day moving average is $636.11. The company has a quick ratio of 2.62, a current ratio of 2.83 and a debt-to-equity ratio of 0.68.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The biotechnology company reported $1.41 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.34 by $0.07. Axon Enterprise had a net margin of 14.86% and a return on equity of 5.81%. The company had revenue of $603.63 million during the quarter, compared to analysts' expectations of $585.67 million. During the same quarter in the prior year, the company earned $1.15 EPS. The firm's revenue was up 31.3% on a year-over-year basis. On average, sell-side analysts anticipate that Axon Enterprise, Inc will post 5.8 earnings per share for the current year.

Wall Street Analyst Weigh In

AXON has been the topic of a number of recent research reports. The Goldman Sachs Group upped their price target on shares of Axon Enterprise from $730.00 to $830.00 and gave the company a "buy" rating in a research note on Wednesday, May 14th. Needham & Company LLC upped their target price on shares of Axon Enterprise from $600.00 to $750.00 and gave the stock a "buy" rating in a report on Thursday, May 8th. Craig Hallum lowered shares of Axon Enterprise from a "buy" rating to a "cautious" rating in a report on Monday, March 10th. Wolfe Research started coverage on shares of Axon Enterprise in a report on Monday. They set an "outperform" rating on the stock. Finally, Barclays upped their target price on shares of Axon Enterprise from $726.00 to $735.00 and gave the stock an "overweight" rating in a report on Friday, May 9th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eleven have given a buy rating to the stock. According to data from MarketBeat, Axon Enterprise has an average rating of "Moderate Buy" and a consensus target price of $699.55.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.